GLP-1
Clinical Guide

Promotional access profile #1

CoreAge Rx

Can the service identify the preparation, prescriber and dispensing pharmacy for the proposed order?

Published offer / checked October 5, 2026

Published starting amounts: semaglutide $99/month; tirzepatide $149/month.

01 / Define the offer

CoreAge Rx advertises compounded semaglutide and tirzepatide, with starting monthly amounts of $99 and $149 respectively. Its pricing help center describes clinician review and shipping within the offer, plus different plan lengths. This briefing records public information checked October 5, 2026; it does not establish individual eligibility or a guaranteed prescription.

02 / Identify the clinical distinction

A compounded product is not FDA-approved. Ask why the specific preparation is proposed, what medical need it addresses and which instructions apply to it. The ingredient name alone does not establish equivalence to every approved medicine discussed in GLP-1 research. The clinician should explain the decision in the context of your history.

03 / Trace responsibility

Request the prescriber's organization and the dispensing pharmacy's name. Ask which team handles a prescription question, which handles a delivery concern and which handles billing. These roles may be connected through one service while still requiring different expertise. Keep the contact details alongside the order information.

04 / Confirm the selected terms

The published plans distinguish one-time purchases from optional subscriptions. CoreAge describes a final-sale point after prescription approval and transmission to the pharmacy. Verify the amount due and the relevant cancellation conditions before payment. A future subscription cancellation and an existing pharmacy order are not the same administrative event.

CoreAge is promotional #1 by publisher selection, and links may earn compensation. We have not verified individual clinicians, inspected a pharmacy or tested the service as patients. This profile provides a structured reading of the public offer. It does not certify clinical quality or decide whether the proposed treatment is appropriate for a particular reader.

Source notes

Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.

  1. CoreAge Rx — semaglutide product offerProvider advertisement
  2. CoreAge Rx — tirzepatide product offerProvider advertisement
  3. CoreAge Rx — pricing and plan termsProvider policy
  4. FDA — compounding questions and answersCompounded-product context

Return to the access comparison →